Gene and cell therapies advance amid a high-profile FDA rejection
Exa-cel is in clinical use, Ultragenyx’s Fayuvi is FDA-approved, REGENXBIO reported positive Phase 3 DMD results, and Nanoscope’s Mogenry BLA was accepted; UniQure’s AMT-130 has priority review and a May 1, 2027 PDUFA date. FDA rejected Capricor’s Duchenne cell therapy, citing unreliable evidence tied to data-integrity and protocol problems and failure to meet the main goals; Capricor disputes the decision, and a resubmission path is unclear.
Sources (2)
Updated Nov 22, 2026